Please assess the completion status of the following clinical trial:

Trial Title: Vitamin Deficiency in Immigrants, a Treatment Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Serum- vitamin D below 75 nmol/L~* Men and female~* 25-65 years of age~* Born in Middle East or Africa, living in Umeå district~Exclusion Criteria:~* Hypersensitive to Cholecalciferol, cocos oil, palm kernel or rubber~* Serum D3 equal to or above75 nmol/L~* Hypercalcemia~* Renal insufficiency~* History of Kidney Calculi~* Nephrocalcinosis~* History of sarcoidosis and other Granulomatous Diseases~* Known malignancy~* Ongoing treatment with phenytoin, barbiturates, rifampicin, isoniazid~* Ongoing treatment with cardiac glycosides~* Ongoing treatment with thiazides~* Ongoing treatment with Etalpha, Rocaltrol, ergocalciferol, Dygratal~* Ongoing treatment with drugs involving fat absorption; Orlistat Colestyramin~* Oral treatment with glucocorticoids~* Ongoing treatment with Aluminum Compounds drugs~* Ongoing treatment with Omega -3, vitamin D and/or calcium~* Immobilisation~* Other medial reason not to participate according to the investigator~* Pregnancy (women with S-D3 below 25 nmol/)~* Breastfeeding

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Vitamin D3, 10 000 IU daily. Treatment to patients with Serum-vitamin D levels below 25 nmol/L
- Group 2a (Type: EXPERIMENTAL): Vitamin D3 2000 IU daily, one of two arms that patients with Serum-vitamin D levels between 25 nmol/L and 49 nmol/l will be randomised to
- Group 2b (Type: EXPERIMENTAL): Vitamin D3 2000 IU weekly, one of two arms that patients with Serum-vitamin D levels between 25 nmol/L and 49 mol/l will be randomised to
- Group 3 (Type: EXPERIMENTAL): Vitamin D3, 2000 IU daily i.e. 3 drops orally once daily for 12 weeks, treatment to patients with Serum-vitamin D levels between 50 and 74 nmol/L

Based on this trial design, predict the completion outcome and termination type (if applicable).